Sironax announced three abstracts on SIR2501 at Neuroscience 2026

Three abstracts on the SARM1 inhibitor SIR2501 were selected for poster presentation at Neuroscience 2026 in Washington, DC. The company reports favorable safety and early evidence of biological activity in patients with amyotrophic lateral sclerosis.

Read the original →